Sotera Health (NASDAQ:SHC) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Sotera Health (NASDAQ:SHC) issued its earnings results on Tuesday. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01), Briefing.com reports. The business had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $0.18 EPS. Sotera Health updated its FY 2024 guidance to 0.670-0.750 EPS and its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

SHC traded down $0.28 on Thursday, hitting $15.83. 1,349,204 shares of the company traded hands, compared to its average volume of 1,307,183. The company has a 50 day moving average of $15.96 and a 200-day moving average of $13.69. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46. The stock has a market capitalization of $4.48 billion, a PE ratio of 63.40 and a beta of 2.08. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 55.12% of the company’s stock.

Analyst Ratings Changes

SHC has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Citigroup increased their price target on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Barclays raised their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.50.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.